EICHORPublic-registry site landscape for NCT03361501, “A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)”, a Hypertriglyceridemia study sponsored by Grace Therapeutics Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03361501 (registry record) |
| Study title | A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) |
| Official title | A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26 Week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia |
| Sponsor | Grace Therapeutics Inc. |
| Condition(s) | Hypertriglyceridemia |
| Phase | PHASE3 |
| Listed sites | 68 |
| Site countries | United States, Canada, Mexico |
Patient-friendly overview of this study: eichor.com/study/NCT03361501.
Eichor generates a preliminary site-risk snapshot for NCT03361501 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Hypertriglyceridemia studies · Weekly briefs
